The Supreme Court of India on October 27 questioned the steep mark-ups charged by private hospitals on cancer medicines after citing a case in which a hospital allegedly charged ₹1.3 lakh for a chemotherapy injection that a medical distributor could procure for ₹11,000. A Bench of Justices Vikram Nath and Sandeep Mehta criticised the disparity while hearing petitions seeking stronger regulation of medicine prices and medical devices. The Centre defended its pricing policies, while representatives of private hospitals cited operational expenses and concerns about the authenticity of medicines purchased outside hospitals. The court reserved its verdict, leaving the question of tighter price controls under consideration.
SC Questions Excessive Medicine Mark-Ups
During the hearing, the Bench referred to the experience of a medical distributor whose wife was undergoing cancer treatment at a prominent private hospital. According to the account presented before the court, the distributor informed hospital authorities that he could procure the chemotherapy injection at a dealer price of ₹11,000. However, the hospital reportedly refused to administer the medicine supplied by him and charged ₹1.30 lakh for the injection.
Questioning the justification for such a substantial difference, the Bench asked, “Can you show any justification for this loot, please? Why this difference? Where does the money go?” The judges also stressed that hospitals must find legitimate ways to cover their operating expenses rather than place an excessive financial burden on patients who have little bargaining power during life-threatening illnesses.
The court raised concerns about other medical supplies as well, citing the example of a saline drip line that reportedly cost around ₹15 at the retail level but was billed to patients at ₹250. These examples prompted broader questions about transparency in hospital billing and whether existing regulations adequately protect patients from excessive charges.
Centre And Private Hospitals Defend Their Positions
The hearing concerned petitions seeking stronger controls over medicine prices, including the initial pricing of non-scheduled medicines, the prescription of generic alternatives and trade margins on medical devices. The proceedings also examined the Centre’s decision to cap trade margins on selected anti-cancer medicines at 30 per cent of their maximum retail price (MRP).
Additional Solicitor General Aishwarya Bhati, representing the Centre, told the Bench that medicine prices in India were among the lowest globally and said the government continued to review its pricing policies. The Centre maintained that regulation had to balance affordability with other considerations affecting the pharmaceutical sector.
Representing private hospitals, senior advocate Mukul Rohatgi argued that hospitals needed revenue to maintain infrastructure, equipment and round-the-clock services. He also raised concerns about patients bringing medicines purchased from outside pharmacies, citing the risk of counterfeit or substandard products. The Bench questioned whether these concerns could justify the steep differences between medicine procurement costs and the amounts billed to patients.
The judges also challenged the government over the limited reach of existing price controls, asking why stronger safeguards could not extend to a wider range of medicines.
What Happens Next In The Medicine Pricing Case?
India’s medicine pricing framework includes the Drugs (Prices Control) Order, 2013, which allows the government to regulate the prices of scheduled medicines. Manufacturers generally have greater flexibility in setting the initial prices of medicines outside the scheduled category, subject to applicable rules.
The government has previously introduced measures to curb excessive trade margins on selected cancer medicines. In 2019, the National Pharmaceutical Pricing Authority intervened to cap trade margins on 42 selected non-scheduled anti-cancer medicines, resulting in price reductions across hundreds of brands.
The latest hearing has renewed questions about whether these measures go far enough, particularly for patients requiring costly, long-term treatment. On October 27, the Supreme Court reserved its verdict on the petitions after hearing the parties. Its observations during the hearing do not, by themselves, introduce a new price cap or establish a final finding against the hospital cited in the example. The eventual decision could influence future regulation of medicine prices and hospital mark-ups.
The Logical Indian’s Perspective
Access to life-saving treatment should not become a source of financial distress for patients and their families. Hospitals have genuine responsibilities, including maintaining safe facilities, employing trained staff and ensuring the quality of medicines. However, these responsibilities must be balanced with transparency, fairness and compassion, especially when patients are already facing the emotional and financial strain of serious illness.
Clearer billing practices, stronger oversight and a meaningful explanation of medicine prices could help build trust between healthcare providers and the people who depend on them. At the same time, fair regulation must account for genuine healthcare costs without allowing patients to bear unjustifiable charges. Affordable treatment is not merely a commercial question; it is also a matter of dignity and public welfare.
What measures do you think India should adopt to make life-saving medicines more affordable while ensuring hospitals can continue to provide quality care?
